Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company focused on aesthetic injectables, and its news flow reflects both commercial execution and product development in this space. Company press releases highlight its mission to build an aesthetic portfolio anchored by Jeuveau, a neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of injectable hyaluronic acid (HA) gels. Readers following EOLS news can see how these product families shape the company’s growth in the self-pay aesthetic market.
News updates frequently cover financial results and guidance, including quarterly net revenue, product mix between global Jeuveau revenue and Evolysse revenue, and commentary on non-GAAP operating income. Management discussions in these releases describe trends in customer accounts, reorder rates, and loyalty program participation through the Evolus Rewards consumer program, providing insight into adoption of the company’s injectables.
Evolus news also features clinical and regulatory milestones for its HA filler portfolio. For example, the company has reported positive topline data from a pivotal study of Evolysse Sculpt, an injectable HA gel product designed to restore mid-face volume, and described the submission of a Premarket Approval application to the U.S. Food and Drug Administration. Additional updates discuss the U.S. commercialization of Evolysse Form and Evolysse Smooth and anticipated timelines for Evolysse Sculpt and Estyme-branded products in Europe.
Investors and industry observers can also find corporate and governance updates in Evolus news, such as executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Together, these items provide a view of how Evolus manages its leadership, capital incentives, and investor outreach as it pursues its performance beauty strategy. Bookmarking the EOLS news page allows users to monitor ongoing developments in financial performance, product launches, clinical data, and corporate actions related to Evolus’ aesthetic injectable business.
Evolus, Inc. (NASDAQ: EOLS) reported strong preliminary financial figures for Q4 2022 and full-year 2022. Q4 net revenue reached approximately
Evolus, Inc. (NASDAQ: EOLS) has announced the extension of the second tranche of its $125 million term loan facility, now available until December 31, 2023. This tranche amounts to $50 million and maintains all previous terms, including interest payments based on the 3-month LIBOR plus 8.5%. The company continues to anticipate reaching cash flow breakeven with its existing cash resources while focusing on expanding its product portfolio. Evolus aims to capitalize on the growing aesthetic neurotoxin market with a customer-centric approach.
Pipeline Medical has announced the addition of Jeuveau® (prabotulinumtoxinA-xvfs) by Evolus (NASDAQ: EOLS) to its offerings. Jeuveau® is a popular botulinum toxin used for aesthetic improvements, particularly for frown lines. With significant market penetration since its launch in 2019, over 8,800 practices have adopted the product, achieving a reorder rate of over 70%. Pipeline Medical aims to enhance access to Jeuveau® through co-branded marketing and competitive pricing, further solidifying its position as a trusted supplier in the MedTech marketplace.
Evolus reported a 27% increase in sales for Q3 2022, reaching $33.9 million, primarily driven by a successful promotional campaign named ‘Switch Your Tox’. The campaign generated $3.5 million in incremental deferred revenue and reported a record of 100,000 consumer redemptions. Evolus maintains its 2022 revenue guidance of $143 to $150 million, projecting year-over-year growth of around 50%. The company's cash position stood at $65.6 million, expected to fund operations to breakeven, as operating expenses decreased to $51.8 million.
Evolus, Inc. (NASDAQ: EOLS), a company focused on beauty products, is participating in two investment conferences in November 2022. The first event is the Stifel 2022 Healthcare Conference on November 15, 2022, from 8:35-9:05 am ET. The second event is the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, from 11:45-12:05 pm ET. Audio webcasts of both events will be available on Evolus’ investor relations website, with replays accessible for 90 days.
Evolus, Inc. (NASDAQ: EOLS) will release its third quarter 2022 financial results on November 8, 2022, after U.S. market close. A conference call will follow at 4:30 p.m. ET, allowing stakeholders to discuss the outcomes and participate in a Q&A session. Interested parties can join via phone at (877) 407-6184 for U.S. or (201) 389-0877 for international calls, or access the live webcast on the Evolus website. A replay will also be available post-call.
Evolus, Inc. (NASDAQ: EOLS) has initiated its commercial operations in Great Britain, marking a significant milestone in its global expansion strategy. The company has shipped its first orders for Nuceiva® (botulinum toxin type A), targeting the UK's largest aesthetic neurotoxins market. Evolus will also launch in Germany and Austria later in 2023 and aims for further European expansion. The company’s commitment to education for healthcare professionals is evident through its Innovator and Early Adopter programs, designed to enhance product understanding and application.
Evolus, Inc. (NASDAQ: EOLS) concluded certain royalty payments from a 2021 settlement with Medytox and Allergan, marking a significant milestone for the company's financial profile. CEO David Moatazedi reported expectations for improved profit margins and a robust growth outlook for 2022. The company anticipates an adjusted gross profit margin increase to 68%-71% for Q4 2022, up from 57.4% in Q2 2022. Additionally, Evolus plans to launch Nuceiva in Europe and is set to present preliminary data from a Phase II study in early 2023.
Evolus, Inc. (NASDAQ: EOLS) announced stock options and restricted stock units (RSUs) granted to Sandra Beaver, the new Chief Financial Officer, on September 5, 2022. These include 169,158 stock options with an exercise price of $9.06 and 36,443 RSUs. The options vest over four years, with 25% vesting annually. This grant complies with Nasdaq Listing Rule 5635(c)(4), emphasizing the company's commitment to attracting and retaining talent. Evolus focuses on innovative beauty products and the aesthetic neurotoxin market through its flagship product, Jeuveau®.
Evolus, Inc. has appointed Sandra Beaver as its new Chief Financial Officer, effective September 5, 2022. With over 20 years of financial expertise, Beaver previously served as Senior Vice President of Finance at Experian, overseeing significant revenue responsibilities. Her experience includes roles at International Game Technology where she led financial planning and analysis. President and CEO David Moatazedi highlighted her potential to enhance Evolus' growth and market share, particularly in the U.S. and Europe.